CollaGenex Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration has approved two phase 3 clinical trials of Col-101, a once-daily, modified-released formulation of doxycycline, 40 mg, for treatment of rosacea.
Deuruxolitinib Shows Efficacy in Hair Regrowth, Patient Satisfaction, and Psychosocial Wellbeing in Severe Alopecia Areata
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Melinda Gooderham, MSc, MD, FRCPC: Insights Into Lebrikizumab’s Sustained 3-Year Efficacy
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Post Hoc Analysis of Vilobelimab in Hidradenitis Suppurativa Suggests Clinically Meaningful Benefits
Upadacitinib Demonstrates Efficacy in Patients With AD and Head and Neck Involvement